Key clinical point: Overall survival was better and quality of life comparable with the addition of lomustine to temozolomide.
Major finding: The only significant difference was a small improvement in Mini-Mental State Exam scores with temozolomide alone, but this was not clinically significant.
Study details: Modified intention-to-treat analysis of 129 patients with MGMT-methylated glioblastoma.
Disclosures: The German Federal Ministry of Education and Research funded the study. Dr. Weller reported having no conflict of interest. Several coauthors reported relationships with industry outside the submitted work.
Weller J et al. Lancet Oncol 2019 Sep 2. doi: 10.1016/S1470-2045(19)30502-9.